Evenity (romosozumab-aqqg) – To treat osteoporosis in postmenopausal women at high risk of fracture.
EVENITY DOSAGE AND ADMINISTRATION
• Two separate subcutaneous injections are needed to administer the total dose of 210 mg. Inject two syringes, one after the other.
• Should be administered by a healthcare provider.
• Administer 210 mg subcutaneously once every month for 12 doses in the abdomen, thigh, or upper arm.
• Adequately supplement calcium and vitamin D during treatment.
EVENITY INDICATIONS AND USAGE
EVENITY is a sclerostin inhibitor indicated for the treatment of osteoporosis in postmenopausal women at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy.
Limitations of Use: Limit duration of use to 12 monthly doses. If osteoporosis therapy remains warranted, continued therapy with an anti-resorptive agent should be considered.
EVENITY ADVERSE REACTIONS
The most common adverse reactions (≥ 5%) reported with EVENITY in clinical trials were arthralgia and headache.